Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (121)	9/10/2001 12:56:56 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 138

Hollis-Eden HIV Drug Effective In Study SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) presented additional clinical results from its South African studies of investigational drug candidate HE2000, an immune regulating hormone, which it said demonstrated that the drug administered to HIV-infected patients had a significant effect on multiple genes implicated in inflammation and immune suppression associated with HIV progression to AIDS, and in a variety of other diseases and conditions of immune dysregulation. The company said in a press release Monday the primary results presented were from a preliminary analysis through the first cycle of dosing of HE2000 administered subcutaneously as a monotherapy to HIV patients in South Africa. The study, in 24 patients, compares to placebo two different doses of HE2000 administered once per day for five days every six weeks. The company said a preliminary analysis of data from a subset of patients from a separate ongoing clinical study in South Africa with a buccal tablet formulation of HE2000 also showed similar increases in inflammatory mediators in HIV patients compared to healthy South African volunteers. Hollis-Eden said HE2000 treatment appears to be generally well tolerated.